TLDR: London-based AI startup ScienceMachine has successfully raised €2.9 million in a pre-seed funding round. This capital injection will accelerate the development and expansion of its autonomous AI agent, ‘Sam,’ which automates complex data analysis for biotech and pharmaceutical companies, aiming to significantly speed up scientific discovery and reduce research costs.
London, UK – July 9, 2025 – ScienceMachine, an innovative artificial intelligence startup based in London, has announced the successful closure of a €2.9 million pre-seed funding round. The significant investment is earmarked to bolster product development and facilitate strategic hiring, particularly within sales and pharma partnerships, as the company prepares to expand its reach from biotech startups to larger pharmaceutical enterprises.
The funding round was co-led by prominent venture capital firms Revent and Nucleus Capital, with additional participation from Juniper and a consortium of strategic angel investors. This financial backing underscores the growing confidence in ScienceMachine’s unique approach to leveraging AI for transformative impact in the life sciences sector.
At the heart of ScienceMachine’s offering is ‘Sam,’ a proprietary autonomous AI agent designed to function as a 24/7 AI bioinformatician. Sam automates the entire data analysis pipeline for biotech and pharma companies, processing vast amounts of experimental data to uncover patterns, insights, and potential breakthroughs without requiring manual intervention. This capability directly addresses a critical bottleneck in biomedical progress: the overwhelming volume of complex biological data coupled with a shortage of skilled data scientists.
Lorenzo Sani, CEO and Co-founder of ScienceMachine, articulated the company’s ambitious vision, stating, “Our goal is to help biopharma make groundbreaking discoveries faster and cheaper. Our AI agent works around the clock, analysing research data from lab to clinic, turning raw data into breakthroughs in hours, instead of months. And we are only at the beginning. We feel like AI will truly transform research and discovery in the coming years.”
Rebecca Brill, Principal at Revent, praised ScienceMachine’s execution, noting, “ScienceMachine is one of the most impressive examples we’ve seen of pure execution. With just two people, they’ve built a product that’s not only best-in-class technically, but already delivering measurable value to customers. They’re perfectly positioned to disrupt one of the largest and most important markets in the world.” Maximilian Schwarz, General Partner at Nucleus, echoed this sentiment, expressing his belief that ‘agent-based architectures will soon become the primary way scientists interact with software.’
Also Read:
- LogicFlo Secures $2.7M to Revolutionize Life Sciences Workflows with Compliant AI Agents
- Oraion Secures $3.5M Pre-Seed Funding to Advance Agentic AI for Enterprises
Remarkably, ScienceMachine has achieved this significant funding and product adoption with a lean team of only two individuals, and, according to reports, without spending ‘a cent on marketing’ or employing a sales team. This efficiency highlights the power of their autonomous AI solution, which enables them to outpace teams many times their size. By integrating directly with existing databases and lab workflows, Sam provides researchers with the analytical output that would typically necessitate an entire team of data scientists, thereby accelerating research and development timelines and reducing operational costs. The company’s success in delivering production-grade AI automation positions it as a key player in revolutionizing data analysis within the biotech and pharmaceutical industries.
